AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32922181 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (OXY)
Number of subjects: 205
Study 32922181 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (FEN)
Number of subjects: 205
Study 32348963 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical system for measuring acoustic startle reflex (ASR)
Number of subjects: 32
Study 32348963 — intervention group
Group type: COMPARATOR
Intervention: EMG system
Number of subjects: 32
Study 35512663 — intervention group
Group type: COMPARATOR
Intervention: Without a mask
Number of subjects: 19
Study 35512663 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 19
Study 35512663 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP2 respirator
Number of subjects: 19
Study 34048682 — intervention group
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine (3–150 μg/kg, administered intravenously once every 3 weeks)
Number of subjects: 133
Study 34048682 — intervention group
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Number of subjects: 133
Study 35906582 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human interleukin‐11 (rhIL‐11) mouthwash
Number of subjects: 112
Study 35906582 — intervention group
Group type: COMPARATOR
Intervention: Kangfuxin fluid
Number of subjects: 112
Study 35906582 — intervention group
Group type: EXPERIMENTAL
Intervention: routine oral care with rhIL‐11 mouthwash
Number of subjects: 112
Study 35906582 — intervention group
Group type: COMPARATOR
Intervention: routine oral care
Number of subjects: 112
Study 33740816 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.33% ropivacaine
Number of subjects: 100
Study 33740816 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 100
Study 34231179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataxic carriers
Number of subjects: 77
Study 34231179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐ataxic carriers
Number of subjects: 77
Study 34231179 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 77
Study 34592390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive structured self-monitoring of blood glucose (ISM)
Number of subjects: 0
Study 34592390 — intervention group
Group type: COMPARATOR
Intervention: Active control (AC)
Number of subjects: 0
Study 36473029 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocin (15 mg daily)
Number of subjects: 64
Study 36473029 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (50 mg daily)
Number of subjects: 64
Study 33604905 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond alexandrite laser (PSAL) with diffractive lens array (DLA)
Number of subjects: 10
Study 32660526 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-operative exercise programme
Number of subjects: 0
Study 32660526 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no formal exercise advice)
Number of subjects: 0
Study 34343420 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of hypertonic saline (0.5 ml)
Number of subjects: 57
Study 34343420 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of hypertonic saline (1.0 ml)
Number of subjects: 57
Study 34343420 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-drawing group
Number of subjects: 57
Study 34343420 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing group
Number of subjects: 57
Study 34343420 — intervention group
Group type: EXPERIMENTAL
Intervention: Momentary pain drawings
Number of subjects: 57
Study 34343420 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak pain intensity
Number of subjects: 57
Study 34746427 — intervention group
Group type: EXPERIMENTAL
Intervention: SaeboGlove plus usual care
Number of subjects: 110
Study 34746427 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 110
Study 32865025 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS)
Number of subjects: 204
Study 32865025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 35219762 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR) 25% for 2 years
Number of subjects: 103
Study 35219762 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (SD)
Number of subjects: 103
Study 33116482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33116482 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,100 µg F−/g
Number of subjects: 60
Study 33116482 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,100 µg F−/g + nano‐HA
Number of subjects: 60
Study 33116482 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 µg F−/g
Number of subjects: 60
Study 33116482 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 µg F−/g + nano‐HA
Number of subjects: 60
Study 33116482 — intervention group
Group type: EXPERIMENTAL
Intervention: nano‐HA without F−
Number of subjects: 60
Study 36069112 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush A
Number of subjects: 18
Study 36069112 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush B
Number of subjects: 18
Study 34915541 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Number of subjects: 36
Study 32131642 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitive and resistive electric transfer (CRet)
Number of subjects: 28
Study 32131642 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot pack (HP)
Number of subjects: 28
Study 32131642 — intervention group
Group type: COMPARATOR
Intervention: Sham CRet
Number of subjects: 28
Study 35745241 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS (resistant starch)
Number of subjects: 80
Study 35745241 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS and KON (konjaku flour)
Number of subjects: 80
Study 35745241 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS and KON
Number of subjects: 80
Study 35745241 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS
Number of subjects: 80
Study 35745241 — intervention group
Group type: EXPERIMENTAL
Intervention: Defecation frequency and serum 5‐HT
Number of subjects: 80
Study 33900322 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal products with low β-glucan viscosity
Number of subjects: 0
Study 33900322 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal products with medium β-glucan viscosity
Number of subjects: 0
Study 33900322 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal products with high β-glucan viscosity
Number of subjects: 0
Study 33900322 — intervention group
Group type: EXPERIMENTAL
Intervention: Kilned samples tempered to 25% moisture and microwaved for 2 minutes
Number of subjects: 0
Study 32306477 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart (0.2 U/kg, single-dose subcutaneous)
Number of subjects: 43
Study 32306477 — intervention group
Group type: COMPARATOR
Intervention: IAsp (0.2 U/kg, single-dose subcutaneous)
Number of subjects: 43
Study 35210345 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training (PBT) protocol, three sessions
Number of subjects: 16
Study 32780994 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low-level laser (LLL) and light-emitting diode (LED) irradiation
Number of subjects: 40
Study 32004201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid hemorrhage (1.4 ml/min, 30‐min bleeding)
Number of subjects: 5
Study 32004201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid‐L hemorrhage (1.4 ml/min, 30‐min bleeding and observation until 6 h)
Number of subjects: 5
Study 32004201 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow hemorrhage (0.1 ml/min, intermittently, 6‐h bleeding)
Number of subjects: 5
Study 32004201 — intervention group
Group type: COMPARATOR
Intervention: Control (30‐min observation)
Number of subjects: 5
Study 32004201 — intervention group
Group type: COMPARATOR
Intervention: Control‐L (6‐h observation)
Number of subjects: 5
Study 33934431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus erlotinib
Number of subjects: 0
Study 33934431 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus erlotinib
Number of subjects: 0
Study 33969505 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pacemaker implantation (<7 days)
Number of subjects: 108
Study 33969505 — intervention group
Group type: COMPARATOR
Intervention: Late pacemaker implantation (≥7 days)
Number of subjects: 108
Study 35123855 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat Aleurone Diet
Number of subjects: 23
Study 35123855 — intervention group
Group type: COMPARATOR
Intervention: Refined Wheat Diet
Number of subjects: 23
Study 32618250 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent travel to high-prevalence areas
Number of subjects: 602620
Study 32618250 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting insecticidal net usage while traveling
Number of subjects: 602620
Study 32618250 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term travel overall
Number of subjects: 602620
Study 35813851 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 mg daily of saffron extract (affron®)
Number of subjects: 62
Study 35813851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 33823845 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching of the fusion of the original CT and MR data 3D model and the original image combined with 3D anatomical image
Number of subjects: 460
Study 33823845 — intervention group
Group type: COMPARATOR
Intervention: Control group teaching method (not specified)
Number of subjects: 460
Study 36410825 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment and colchicine
Number of subjects: 60
Study 36410825 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment only
Number of subjects: 60
Study 36410825 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine only
Number of subjects: 60
Study 36410825 — intervention group
Group type: COMPARATOR
Intervention: Control/delayed periodontal treatment
Number of subjects: 60
Study 36410825 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 32075474 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyphthalide injection combined with urinary kallikrein
Number of subjects: 110
Study 32075474 — intervention group
Group type: COMPARATOR
Intervention: Cinepazide maleate injection combined with alprostadil injection
Number of subjects: 110
Study 32075474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 32087356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endocardial/epicardial mapping and ablation (endo/epi)
Number of subjects: 30
Study 32087356 — intervention group
Group type: COMPARATOR
Intervention: Endocardial mapping and ablation (endo)
Number of subjects: 30
Study 35581997 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melatonin (21 mg per day for 5 days)
Number of subjects: 67
Study 35581997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 32138784 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg/kg dexmedetomidine (DEX2)
Number of subjects: 126
Study 32138784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 126
Study 32138784 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including DEX1, DEX2, and Placebo)
Number of subjects: 126
Study 616117878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 973
Study 616117878 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 973
Study 36250283 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative multimodal nutrition intervention
Number of subjects: 49
Study 36250283 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 49
Study 35804297 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay Strong app
Number of subjects: 156
Study 34129855 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen-deprivation therapy (ADT) + docetaxel (D)
Number of subjects: 160
Study 34129855 — intervention group
Group type: COMPARATOR
Intervention: Androgen-deprivation therapy (ADT) alone
Number of subjects: 160
Study 34129855 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Decipher risk and lower AR-A
Number of subjects: 160
Study 33516592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, stage-matched intervention
Number of subjects: 533
Study 33516592 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 533
Study 33516592 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy instrument (SE-HTA)
Number of subjects: 533
Study 32249788 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive peripheral magnetic stimulation (rPMS) applied to the trapezius muscles (n=19)
Number of subjects: 37
Study 32249788 — intervention group
Group type: COMPARATOR
Intervention: Repetitive peripheral magnetic stimulation (rPMS) applied to the deltoid muscles (n=18)
Number of subjects: 37
Study 35473663 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rFSAV (60 μg)
Number of subjects: 144
Study 35473663 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-dose rFSAV (120 μg)
Number of subjects: 144
Study 35473663 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rFSAV (240 μg)
Number of subjects: 144
Study 35473663 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-adjusted rFSAV (90 μg) in phase 1b
Number of subjects: 144
Study 35473663 — intervention group
Group type: EXPERIMENTAL
Intervention: All rFSAV doses
Number of subjects: 144
Study 35473663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 35000952 — intervention group
Group type: EXPERIMENTAL
Intervention: XP‐endo Finisher R (XPF‐R)
Number of subjects: 30
Study 35000952 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne Gold (WOG)
Number of subjects: 30
Study 35000952 — intervention group
Group type: EXPERIMENTAL
Intervention: TruNatomy (TRN)
Number of subjects: 30
Study 36497687 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized oral health care training (IndOHCT)
Number of subjects: 74
Study 36497687 — intervention group
Group type: COMPARATOR
Intervention: Information flyer (Control group)
Number of subjects: 74
Study 33248282 — intervention group
Group type: EXPERIMENTAL
Intervention: sIgE to Ara h 2
Number of subjects: 154
Study 33248282 — intervention group
Group type: EXPERIMENTAL
Intervention: sIgE to Ara h 6
Number of subjects: 154
Study 33248282 — intervention group
Group type: EXPERIMENTAL
Intervention: sIgE to peanut extract
Number of subjects: 154
Study 32701900 — intervention group
Group type: EXPERIMENTAL
Intervention: Snus (8 mg nicotine)
Number of subjects: 10
Study 32701900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 36145080 — intervention group
Group type: EXPERIMENTAL
Intervention: BR (11.8 mmol NO3− per day)
Number of subjects: 14
Study 36145080 — intervention group
Group type: COMPARATOR
Intervention: PL (0.10 mmol NO3− per day)
Number of subjects: 14
Study 32941386 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-based research articles post-ARRIVE guidelines
Number of subjects: 100
Study 32941386 — intervention group
Group type: COMPARATOR
Intervention: Animal-based research articles pre-ARRIVE guidelines
Number of subjects: 100
Study 35476860 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7-mm transmucosal abutment height
Number of subjects: 60
Study 35476860 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4-mm transmucosal abutment height
Number of subjects: 60
Study 33949940 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen-only pill (75 microg of desogestrel) plus rapid access card to a sexual and reproductive health clinic
Number of subjects: 636
Study 33949940 — intervention group
Group type: COMPARATOR
Intervention: Control group advised to attend their usual contraceptive provider
Number of subjects: 636
Study 33250388 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction drainage (Group 1)
Number of subjects: 150
Study 33250388 — intervention group
Group type: COMPARATOR
Intervention: Control (no drainage) (Group 2)
Number of subjects: 150
Study 33250388 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 150
Study 36471334 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation or medical care (specific types not detailed)
Number of subjects: 90
Study 33320067 — intervention group
Group type: EXPERIMENTAL
Intervention: TARE with US-triggered microbubble destruction
Number of subjects: 28
Study 33320067 — intervention group
Group type: COMPARATOR
Intervention: TARE
Number of subjects: 28
Study 33893754 — intervention group
Group type: EXPERIMENTAL
Intervention: evolocumab 140 mg s.c. every 2 weeks on top of ongoing LLT
Number of subjects: 100
Study 33893754 — intervention group
Group type: COMPARATOR
Intervention: ongoing LLT alone
Number of subjects: 100
Study 32742642 — intervention group
Group type: EXPERIMENTAL
Intervention: 2RDA (2 times the recommended dietary intake of protein, 1.6 g protein/kg body weight per day)
Number of subjects: 28
Study 32742642 — intervention group
Group type: COMPARATOR
Intervention: RDA (recommended dietary intake of protein, 0.8 g protein/kg body weight per day)
Number of subjects: 28
Study 34474421 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruch membrane opening-minimum rim width (BMO-MRW)
Number of subjects: 253
Study 34474421 — intervention group
Group type: COMPARATOR
Intervention: peripapillary retinal nerve fiber layer (pRNFL) thickness
Number of subjects: 253
Study 36513483 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arg supplementation (3 g oral daily for up to 10 days)
Number of subjects: 74
Study 36513483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 33206991 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Number of subjects: 0
Study 33206991 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed and cisplatin or carboplatin)
Number of subjects: 0
Study 33949711 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD)
Number of subjects: 0
Study 33949711 — intervention group
Group type: COMPARATOR
Intervention: Control (no diet change)
Number of subjects: 0
Study 32162109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal–iliohypogastric nerve block (IINB and IHNB) with tumescent anaesthesia
Number of subjects: 75
Study 32162109 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 75
Study 35971267 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin
Number of subjects: 29
Study 35971267 — intervention group
Group type: COMPARATOR
Intervention: Absorbable gelatine
Number of subjects: 29
Study 33984498 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology (20 min sessions, 4 times over 2 weeks)
Number of subjects: 45
Study 33984498 — intervention group
Group type: COMPARATOR
Intervention: Placebo foot reflexology (noneffective touch, 20 min sessions, 4 times over 2 weeks)
Number of subjects: 45
Study 32151214 — intervention group
Group type: EXPERIMENTAL
Intervention: Video psychoeducation
Number of subjects: 556
Study 32151214 — intervention group
Group type: COMPARATOR
Intervention: Informational brochure
Number of subjects: 556
Study 35724841 — intervention group
Group type: EXPERIMENTAL
Intervention: Public Commitment
Number of subjects: 1530
Study 35724841 — intervention group
Group type: EXPERIMENTAL
Intervention: Private Commitment
Number of subjects: 1530
Study 35724841 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmark Peer Comparison
Number of subjects: 1530
Study 35724841 — intervention group
Group type: EXPERIMENTAL
Intervention: Trending
Number of subjects: 1530
Study 35724841 — intervention group
Group type: COMPARATOR
Intervention: Control (Commitment)
Number of subjects: 1530
Study 35724841 — intervention group
Group type: COMPARATOR
Intervention: Control (Performance Feedback)
Number of subjects: 1530
Study 34333991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training plus moderate caloric restriction (CR); n=55
Number of subjects: 160
Study 34333991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training plus more intensive caloric restriction (CR); n=49
Number of subjects: 160
Study 34333991 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise training only; n=56
Number of subjects: 160
Study 35701050 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted expectation management aiming to reduce illness-related anxiety and dysfunctional symptom expectations in addition to standard care (SC)
Number of subjects: 234
Study 35701050 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific supportive treatment in addition to standard care (SC)
Number of subjects: 234
Study 35701050 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC) only
Number of subjects: 234
Study 33267769 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mosapride (5 mg) before and after surgery with dexamethasone (10 mg)
Number of subjects: 240
Study 33267769 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg) before anesthesia induction
Number of subjects: 240
Study 33267769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 35723120 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive transcranial magnetic stimulation (rTMS) combined with functional electrical stimulation (FES)
Number of subjects: 60
Study 35723120 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 60
Study 35723120 — intervention group
Group type: COMPARATOR
Intervention: Functional electrical stimulation (FES)
Number of subjects: 60
Study 33845869 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle Years Yoga (GYY) programme for 12 weeks
Number of subjects: 0
Study 33845869 — intervention group
Group type: COMPARATOR
Intervention: No offer (control group)
Number of subjects: 0
Study 32750714 — intervention group
Group type: EXPERIMENTAL
Intervention: Project SEARCH plus ASD Supports (PS+ASD)
Number of subjects: 0
Study 32750714 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32750714 — intervention group
Group type: EXPERIMENTAL
Intervention: PS+ASD
Number of subjects: 0
Study 35532982 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 51
Study 35532982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51